Vertex Pharmaceuticals Inc. closed 14.97% short of its 52-week high of $519.88, which the company achieved on November 8th.

My name is Will Pickering. I cover U.S. Biotech at Bernstein. I am privileged to be joined today by Vertex's CEO, Reshma Kewalramani. And Reshma, welcome. Sure. Sounds good. Well, good morning ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the company's innovation. The three major indexes slid in March and April as ...

Veteran biopharma executive, Michael P. Cooke, PhD, joins Stratus to accelerate development of its pioneering Stratus Prime™ hematopoietic stem cell platformCAMBRIDGE, Mass., June 02, 2025 (GLOBE ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated ...

NanoViricides (NNVC) is presenting at the prestigious BIO International Convention on June 16th, showcasing their revolutionary broad-spectrum antiviral platform that could transform how we treat ...